Black Titan (NASDAQ:BTTC – Get Free Report) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its peers? We will compare Black Titan to similar companies based on the strength of its profitability, analyst recommendations, valuation, institutional ownership, earnings, risk and dividends.
Earnings and Valuation
This table compares Black Titan and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Black Titan | $2.68 million | -$4.71 million | -0.61 |
| Black Titan Competitors | $233.36 million | -$56.16 million | -10.51 |
Black Titan’s peers have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Titan | 1 | 0 | 0 | 0 | 1.00 |
| Black Titan Competitors | 100 | 199 | 219 | 12 | 2.27 |
As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 129.33%. Given Black Titan’s peers stronger consensus rating and higher probable upside, analysts clearly believe Black Titan has less favorable growth aspects than its peers.
Institutional and Insider Ownership
56.0% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 53.7% of Black Titan shares are held by insiders. Comparatively, 16.3% of shares of all “Services – Computer Programming And Data Processing” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Black Titan and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Titan | N/A | -108.60% | -95.64% |
| Black Titan Competitors | -51.37% | -912.76% | -63.13% |
Volatility & Risk
Black Titan has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s peers have a beta of 0.68, meaning that their average stock price is 32% less volatile than the S&P 500.
Summary
Black Titan peers beat Black Titan on 7 of the 13 factors compared.
About Black Titan
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
